Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VERAPAMIL HCL

All products: general benefit

Other products in the same Health Canada class (C08D) — coverage varies; not interchangeable

  • Diltiazem (Tiazac XC): general benefit, Not a benefit

AA-Verap · DIN 00782491 · 120mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Verap · DIN 00782491 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $1.2750 Health Canada: Marketed since 2026-03-24 · brand AA-VERAP · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Verap: Formulary list price $0.4250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9940 · Verify on the e-Formulary ↗ (DIN 00782491)

Source record
DIN 00782491: AA-Verap Raw flags: chronicUseMed=Y, sec3=Y Item: 240400050; group id 293; item number 0636; lccId None; manufacturer id AAP Source form: Tab; strength: 120mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4250; ministry $0.4250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782491 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9940
Interchangeable products
Isoptin · DIN 00554324 · not recorded Mylan-Verapamil · DIN 02237922 · $0.4250
Shortage status: resolved shortage (ended 2026-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782491
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: angina resulting from coronary artery spasm
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NIFEDIPINE · General benefit (5), Listed, not a benefit (3) 1 INDICATIONS NIFEDIPINE (nifedipine capsules) is indicated for: • Management of angina resulting from coronary artery spasm. PM: https://pdf.hres.ca/dpd_pm/00073685.PDF; date JUN 16, 2010; DIN 00725110; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS AA-VERAP (verapamil hydrochloride tablets) is indicated for: • Chronic stable angina of effort. • Angina resulting from coronary artery spasm. • Obstructive hypertrophic cardiomyopathy, where surgery is not otherwise indicated. • Atrial fibrillation or flutter with rapid ventricular response not otherwise controllable with digitalis preparations. • Follow-up treatment to the use of injectable verapamil hydrochloride in paroxysmal supraventricular tachycardia. • Treatment of mild to moderate essential hypertension. Concomitant use of verapamil hydrochloride with a diuretic or an angiotensin converting enzyme inhibitor has been shown to be compatible and to have additive blood pressure lowering effects. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Caution should be exercised when verapamil hydrochloride is admi… https://pdf.hres.ca/dpd_pm/00082059.PDF PM date: JUN 30, 1989 Source product: AA-VERAP; DIN 00782483; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.